Michael D. Blaszyk - 18 Jun 2025 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Reporting relationship: Director
Issuer ticker: IBRX
Reported as of: 18 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jun 2025, 18:34:38 UTC
Prior SEC filing: 13 Jun 2024
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jason Liljestrom, as Attorney-in-Fact

Key filing fact

Michael D. Blaszyk filed Form 4 for ImmunityBio, Inc. (IBRX) on 20 Jun 2025.

Key facts

This page summarizes Michael D. Blaszyk's Form 4 filing for ImmunityBio, Inc. (IBRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Jun 2025, 18:34.

Change

Previous filing in this sequence was filed on 13 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001371407 Primary reporting owner

BLASZYK MICHAEL D

Relationship: Director
Address: C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO
Signature: /s/ Jason Liljestrom, as Attorney-in-Fact
Signature date: 20 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +162,786
Change %
Price: $0.000000
Shares after: 162,786
Date: 18 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 162,786
Exercise price: $2.84
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.